Wave Life Sciences Ltd (NASDAQ:WVE) Given Consensus Rating of “Buy” by Brokerages

Shares of Wave Life Sciences Ltd (NASDAQ:WVE) have been assigned a consensus rating of “Buy” from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $44.00.

A number of brokerages have weighed in on WVE. HC Wainwright set a $33.00 price target on Wave Life Sciences and gave the stock a “buy” rating in a report on Wednesday, October 9th. Mizuho reiterated a “buy” rating on shares of Wave Life Sciences in a research report on Wednesday, September 25th. Cowen reiterated a “hold” rating on shares of Wave Life Sciences in a research report on Tuesday, July 30th. BidaskClub upgraded shares of Wave Life Sciences from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, ValuEngine upgraded shares of Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 29th.

Large investors have recently modified their holdings of the company. Clear Street Markets LLC acquired a new stake in Wave Life Sciences in the second quarter valued at approximately $575,000. Bailard Inc. raised its holdings in Wave Life Sciences by 97.6% during the second quarter. Bailard Inc. now owns 83,000 shares of the company’s stock worth $2,165,000 after acquiring an additional 41,000 shares in the last quarter. Aperio Group LLC bought a new stake in Wave Life Sciences during the second quarter worth about $51,000. Janus Henderson Group PLC raised its holdings in Wave Life Sciences by 16.1% during the second quarter. Janus Henderson Group PLC now owns 3,392,298 shares of the company’s stock worth $88,505,000 after acquiring an additional 470,402 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale bought a new stake in Wave Life Sciences during the second quarter worth about $604,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

WVE traded up $0.33 on Friday, hitting $27.71. 184,790 shares of the company were exchanged, compared to its average volume of 333,724. Wave Life Sciences has a 12 month low of $17.59 and a 12 month high of $50.98. The company has a market cap of $925.23 million, a PE ratio of -5.48 and a beta of 0.80. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.33 and a current ratio of 2.33. The stock’s fifty day moving average is $22.19 and its 200-day moving average is $23.77.

Wave Life Sciences (NASDAQ:WVE) last released its earnings results on Tuesday, November 5th. The company reported ($1.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.14). Wave Life Sciences had a negative return on equity of 121.80% and a negative net margin of 1,015.84%. The company had revenue of $2.93 million for the quarter, compared to the consensus estimate of $6.30 million. As a group, equities research analysts expect that Wave Life Sciences will post -5.41 EPS for the current fiscal year.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Read More: Example of operating income, EBIT and EBITDA

Analyst Recommendations for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply